Two introduced drugs, sotorasib (AMG 510) and adagrasib (MRTX849), were approved for the treatment of advanced non-small cell lung cancer (NSCLC) patients harboring the KRAS G12C (c.34G>T, p.Gly12Cys) mutation who have been previously treated with at least one systemic therapy. Here, KRAS is linked to non-small cell lung carcinoma.